KRAS and pancreatic neoplasm: The knockdown of TRIM37 in mouse pancreatic cancer cell line Pan18 and human pancreatic cancer cell lines, PANC-1 with KRAS mutation and BxPC-3 with wild-type KRAS, resulted in a significant reduction in the viability of pancreatic cancer cells.